Lentiviral vectors are advanced gene delivery tools that provide stable integration and long-term expression of transgenes in both dividing and non-dividing cells. They have emerged as one of the most efficient gene therapy platforms owing to their ability to transduce neurons and stem cells. Lentiviral vectors have been extensively utilized for developing therapies for genetic disorders like hemophilia, cancer and more. They are delivered directly to target cells and aid in introducing genetic material into the human genome for therapeutic benefits. Some key advantages of lentiviral vectors include wider host range, ability to efficiently transduce non-dividing cells and efficient gene delivery.

The global lentiviral vectors market is estimated to be valued at US$ 292 Mn in 2023 and is expected to exhibit a CAGR of 18% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:

One of the major trends driving the growth of the lentiviral vectors market is the increasing number of clinical trials for the development of gene and cell therapies. According to the Genetic Engineering & Biotechnology News, around 900 gene therapy clinical trials were under progress as of March 2022. Out of these, over 70% trials utilized lentiviral or retroviral vectors for gene delivery. Companies like bluebird bio and Novartis are investigating lentiviral vectors based therapies for hemophilia. Increased funding for research and development of novel gene therapies is further fueling clinical research activities and thereby contributing to the market growth over the forecast period.

Porter’s Analysis

Threat of new entrants: Low barriers for startups to enter the market with low production costs and high demand for lentiviral vectors makes the threat of new entrants moderate.

Bargaining power of buyers: Large pharmaceutical and biotech companies hold high bargaining power over pricing due to their large purchase volumes.

Bargaining power of suppliers: Few global players, specialized expertise required and longterm relationships make suppliers hold moderate bargaining power.

Threat of new substitutes: Alternatives like adenoviral vectors pose limited threat currently due to lentiviral vector’s superiority in stable gene integration.

Competitive rivalry: Intense competition among global players to acquire market share and expand production capacity through capacity expansions and strategic collaborations.

Key Takeaways

The global Lentiviral Vectors Market Growth is expected to witness high growth over the forecast period. North America currently dominates the market owing to strong foothold of global key players and frequent product launches.

Regional analysis:

North America is expected to hold the largest share of over 35% in the global lentiviral vectors market owing to robust research funding, presence of major companies, and advanced facilities for R&D activities in the US and Canada. Europe and Asia Pacific regions are also expected to witness high growth rates over next few years due to increasing focus on gene therapy research.

Key players:

Key players operating in the lentiviral vectors market are Thermo Fisher Scientific Inc., Sirion-Biotech GmbH (Revvity), Vector Biolabs, OriGene Technologies, Inc., SignaGen Laboratories, Sino Biological, Inc., Takara Bio Inc., Cell Biolabs, Inc., and GenTarget Inc. These players are focusing on new product developments and capacity expansion activities to strengthen their market position.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it